Skip to main content
Top
Published in: AIDS and Behavior 3/2018

01-03-2018 | Original Paper

“It’s Never Just About the HIV:” HIV Primary Care Providers’ Perception of Substance Use in the Era of “Universal” Antiretroviral Medication Treatment

Authors: Aimee N. C. Campbell, Margaret Wolff, Laurel Weaver, Don Des Jarlais, Susan Tross

Published in: AIDS and Behavior | Issue 3/2018

Login to get access

Abstract

Antiretroviral therapy (ART) is recommended for all people living with HIV (PLWH), regardless of disease status. Substance use disorders (SUD) are common barriers to successful HIV treatment; however, few studies have comprehensively explored how HIV primary care providers take SUDs into account in the context of universal ART implementation. This study uses thematic analysis of qualitative interviews to explore providers’ (N = 25) substance use assessment and factors associated with ART initiation. 64% of providers had 15 or more years of HIV treatment experience. Almost all providers agreed with the guidelines for universal ART initiation despite the presence of SUD. Still, identification and management of SUD is challenged by inconsistent assessment, providers’ misperceptions about SUD and patients’ willingness to discuss it, and lack of accessible treatment resources when SUD is identified. Greater guidance in systematic SUD assessment and management, combined with integrated addiction services, could enhance universal ART implementation among PLWH/SUD.
Literature
3.
go back to reference The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic infection. N Eng J Med. 2015;373:795–807.CrossRef The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic infection. N Eng J Med. 2015;373:795–807.CrossRef
4.
go back to reference The TEMPRANO ANRS 12136 Study Group. A trial of early antiretroviral and isoniazid preventive therapy in Africa. N Eng J Med. 2015;373:808–22.CrossRef The TEMPRANO ANRS 12136 Study Group. A trial of early antiretroviral and isoniazid preventive therapy in Africa. N Eng J Med. 2015;373:808–22.CrossRef
7.
go back to reference Cohen MS, Holmes C, Padian N, et al. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff. 2012;31(7):1439–49.CrossRef Cohen MS, Holmes C, Padian N, et al. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff. 2012;31(7):1439–49.CrossRef
8.
go back to reference Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531–6.CrossRefPubMed Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531–6.CrossRefPubMed
9.
go back to reference Wood E, Milloy MJ, Montaner JS. HIV treatment as prevention among injection drug users. Curr Opin HIV AIDS. 2012;17(2):151–6.CrossRef Wood E, Milloy MJ, Montaner JS. HIV treatment as prevention among injection drug users. Curr Opin HIV AIDS. 2012;17(2):151–6.CrossRef
10.
go back to reference Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2(4):194–9.CrossRefPubMed Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2(4):194–9.CrossRefPubMed
11.
go back to reference Des Jarlais DC, Arasteh K, Perlis T, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS. 2007;21:231–5.CrossRefPubMed Des Jarlais DC, Arasteh K, Perlis T, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS. 2007;21:231–5.CrossRefPubMed
12.
go back to reference Hutton HE, Lyketsos CG, Zenilman JM, Thompson RE, Erbelding EJ. Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. Am J Psychiatr. 2004;161(5):912–4.CrossRefPubMed Hutton HE, Lyketsos CG, Zenilman JM, Thompson RE, Erbelding EJ. Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. Am J Psychiatr. 2004;161(5):912–4.CrossRefPubMed
13.
go back to reference Raj A, Saitz R, Cheng DM, Winter M, Samet JH. Associations between alcohol, heroin and cocaine use and high risk sexual behaviors among detoxification patients. Am J Drug Alcohol Abuse. 2007;33:169–78.CrossRefPubMed Raj A, Saitz R, Cheng DM, Winter M, Samet JH. Associations between alcohol, heroin and cocaine use and high risk sexual behaviors among detoxification patients. Am J Drug Alcohol Abuse. 2007;33:169–78.CrossRefPubMed
14.
go back to reference Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C. Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission. Am J Psychiatr. 2007;164(1):157–60.CrossRefPubMed Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C. Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission. Am J Psychiatr. 2007;164(1):157–60.CrossRefPubMed
15.
go back to reference Zule WA, Costenbader E, Coomes CM, et al. Stimulant use and sexual risk behaviors for HIV in rural North Carolina. J Rural Health. 2007;23:S73–8.CrossRef Zule WA, Costenbader E, Coomes CM, et al. Stimulant use and sexual risk behaviors for HIV in rural North Carolina. J Rural Health. 2007;23:S73–8.CrossRef
16.
go back to reference Metsch LR, Bell C, Pereya M, et al. Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Public Health. 2009;6:1045–9.CrossRef Metsch LR, Bell C, Pereya M, et al. Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Public Health. 2009;6:1045–9.CrossRef
17.
go back to reference Bell C, Metsch LR, Vogenthaler N, et al. Never in care: characteristics of HIV-infected crack cocaine users in two U.S. cities who have never been to outpatient HIV care. J Acquir Immune Defic Syndr. 2010;54(4):376–80.CrossRefPubMedPubMedCentral Bell C, Metsch LR, Vogenthaler N, et al. Never in care: characteristics of HIV-infected crack cocaine users in two U.S. cities who have never been to outpatient HIV care. J Acquir Immune Defic Syndr. 2010;54(4):376–80.CrossRefPubMedPubMedCentral
18.
go back to reference Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of anti-retroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16(9):625–33.CrossRefPubMedPubMedCentral Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of anti-retroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16(9):625–33.CrossRefPubMedPubMedCentral
19.
go back to reference Hall HI, Walker F, Shah D, Belle E. Trends in HIV diagnoses and testing among U.S. adolescents and young adults. AIDS Behav. 2012;16(1):36–43.CrossRefPubMed Hall HI, Walker F, Shah D, Belle E. Trends in HIV diagnoses and testing among U.S. adolescents and young adults. AIDS Behav. 2012;16(1):36–43.CrossRefPubMed
20.
go back to reference Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81.CrossRefPubMedPubMedCentral Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81.CrossRefPubMedPubMedCentral
21.
go back to reference Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21–22):948–52.CrossRefPubMed Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21–22):948–52.CrossRefPubMed
22.
go back to reference Milloy MS, Marshall BDL, Kerr T, Buxton J, Rhodes T, Montaner J, et al. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS. 2012;26:1049–63.CrossRefPubMedPubMedCentral Milloy MS, Marshall BDL, Kerr T, Buxton J, Rhodes T, Montaner J, et al. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS. 2012;26:1049–63.CrossRefPubMedPubMedCentral
23.
go back to reference Andand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–26.CrossRef Andand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–26.CrossRef
24.
go back to reference Weiser J, Brooks JT, Skarbinski J, et al. Barriers to universal prescribing of antiretroviral therapy by HIV care providers in the United States, 2013–2014. J Acquir Immune Defic Syndr. 2017;74(5):479–87.CrossRefPubMedPubMedCentral Weiser J, Brooks JT, Skarbinski J, et al. Barriers to universal prescribing of antiretroviral therapy by HIV care providers in the United States, 2013–2014. J Acquir Immune Defic Syndr. 2017;74(5):479–87.CrossRefPubMedPubMedCentral
26.
go back to reference Beer L, Valverde EE, Raiford JL, Weister J, White BL, Skarbinski J. Clinician perspectives on delaying initiation of antiretroviral therapy for clinically eligible HIV-infected patients. J Int Assoc Provid AIDS Care. 2015;14(3):246–54.CrossRef Beer L, Valverde EE, Raiford JL, Weister J, White BL, Skarbinski J. Clinician perspectives on delaying initiation of antiretroviral therapy for clinically eligible HIV-infected patients. J Int Assoc Provid AIDS Care. 2015;14(3):246–54.CrossRef
27.
go back to reference Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–9.CrossRefPubMedPubMedCentral Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–9.CrossRefPubMedPubMedCentral
28.
go back to reference Kurth AE, Mayer K, Beauchamp G, et al. Clinician practices and attitudes regarding early antiretroviral therapy in the US. J Acquir Immune Defic Snydr. 2012;61(5):e65.CrossRef Kurth AE, Mayer K, Beauchamp G, et al. Clinician practices and attitudes regarding early antiretroviral therapy in the US. J Acquir Immune Defic Snydr. 2012;61(5):e65.CrossRef
29.
go back to reference Westergaard RP, Ambrose BK, Mehta SH, Kirk GD. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc. 2012;15(1):1.CrossRef Westergaard RP, Ambrose BK, Mehta SH, Kirk GD. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc. 2012;15(1):1.CrossRef
30.
go back to reference Krakower DS, Oldenburg CE, Mitty JA, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10(7):e0132398.CrossRefPubMedPubMedCentral Krakower DS, Oldenburg CE, Mitty JA, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10(7):e0132398.CrossRefPubMedPubMedCentral
31.
go back to reference Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Diffusion of newer HIV prevention innovations: variable practices of frontline infectious diseases physicians. Clin Infect Dis. 2016;62(1):99–105.CrossRefPubMed Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Diffusion of newer HIV prevention innovations: variable practices of frontline infectious diseases physicians. Clin Infect Dis. 2016;62(1):99–105.CrossRefPubMed
32.
go back to reference Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians’ judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Mak. 2001;21:28–36.CrossRef Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians’ judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Mak. 2001;21:28–36.CrossRef
35.
go back to reference Montague BT, Kahler CW, Colby SM, et al. Attitudes and training needs of New England HIV care and addiction treatment providers: opportunities for better integration of HIV and alcohol treatment services. Addict Disord Their Treat. 2015;14(1):16–28.CrossRefPubMedPubMedCentral Montague BT, Kahler CW, Colby SM, et al. Attitudes and training needs of New England HIV care and addiction treatment providers: opportunities for better integration of HIV and alcohol treatment services. Addict Disord Their Treat. 2015;14(1):16–28.CrossRefPubMedPubMedCentral
36.
go back to reference Gagliardo C, Murray M, Saiman L, Neu N. Initiation of antiretroviral therapy in youth with HIV: a US-based provider survey. AIDS Patient Care STDs. 2013;27(9):498–502.CrossRefPubMedPubMedCentral Gagliardo C, Murray M, Saiman L, Neu N. Initiation of antiretroviral therapy in youth with HIV: a US-based provider survey. AIDS Patient Care STDs. 2013;27(9):498–502.CrossRefPubMedPubMedCentral
37.
go back to reference Lee L, Rand CS, Ellen JM, Agwu AL. Factors informing HIV providers’ decisions to start antiretroviral therapy for young people living with behaviorally acquired HIV. J Adolesc Health. 2014;55(3):358–65.CrossRefPubMedPubMedCentral Lee L, Rand CS, Ellen JM, Agwu AL. Factors informing HIV providers’ decisions to start antiretroviral therapy for young people living with behaviorally acquired HIV. J Adolesc Health. 2014;55(3):358–65.CrossRefPubMedPubMedCentral
38.
go back to reference Loughlin AI, Metsch L, Gardner L, Anderson-Mahoney P, Barrigan M, Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care. 2004;16(4):485–500.CrossRefPubMed Loughlin AI, Metsch L, Gardner L, Anderson-Mahoney P, Barrigan M, Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care. 2004;16(4):485–500.CrossRefPubMed
39.
go back to reference Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance use stigma: reliability and validity of theory-based scale for substance using populations. Drug Alcohol Depend. 2016;162:34–43.CrossRefPubMedPubMedCentral Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance use stigma: reliability and validity of theory-based scale for substance using populations. Drug Alcohol Depend. 2016;162:34–43.CrossRefPubMedPubMedCentral
40.
go back to reference Chang J, Dubbin L, Shim J. Negotiating substance use stigma: the role of cultural health capital in provider-patient interactions. Sociol Health Illn. 2016;38(1):90–108.CrossRefPubMed Chang J, Dubbin L, Shim J. Negotiating substance use stigma: the role of cultural health capital in provider-patient interactions. Sociol Health Illn. 2016;38(1):90–108.CrossRefPubMed
41.
go back to reference Mao L, Adam PC, Kippax S, et al. Evolving views and practices of antiretroviral treatment prescribers in Australia. Med J Aust. 2015;202(5):258–61.CrossRefPubMed Mao L, Adam PC, Kippax S, et al. Evolving views and practices of antiretroviral treatment prescribers in Australia. Med J Aust. 2015;202(5):258–61.CrossRefPubMed
42.
go back to reference Campbell AN, Des Jarlais D, Cooper H, et al. Antiretroviral medication treatment for all HIV-infected individuals: a protocol using innovative multilevel methodologies to evaluate New York City’s universal ART policy among problem substance users. BMC Health Serv Res. 2016. https://doi.org/10.1186/s12913-016-1554-8. Campbell AN, Des Jarlais D, Cooper H, et al. Antiretroviral medication treatment for all HIV-infected individuals: a protocol using innovative multilevel methodologies to evaluate New York City’s universal ART policy among problem substance users. BMC Health Serv Res. 2016. https://​doi.​org/​10.​1186/​s12913-016-1554-8.
46.
go back to reference Dramschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorder treatment. Psychol Addict Behav. 2011;25(2):194–205.CrossRef Dramschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorder treatment. Psychol Addict Behav. 2011;25(2):194–205.CrossRef
47.
go back to reference Corbin J, Strauss A. Grounded theory method: procedures, canons, and evaluative criteria. Qual Sociol. 1990;13(1):3–21.CrossRef Corbin J, Strauss A. Grounded theory method: procedures, canons, and evaluative criteria. Qual Sociol. 1990;13(1):3–21.CrossRef
48.
go back to reference Strauss A, Corbin J. Grounded theory methodology. In: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. Thousand Oaks: Sage; 1994. p. 273–85. Strauss A, Corbin J. Grounded theory methodology. In: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. Thousand Oaks: Sage; 1994. p. 273–85.
49.
go back to reference Ritchie J, Lewis J, Nicholls CM, Ormston R. Qualitative research practice: a guide for social science and researchers. 2nd ed. London: Sage; 2014. Ritchie J, Lewis J, Nicholls CM, Ormston R. Qualitative research practice: a guide for social science and researchers. 2nd ed. London: Sage; 2014.
50.
go back to reference Ritchie J, Spencer L. Analyzing qualitative data. In: Bryman A, Burgess RG, editors. Qualitative data analysis for applied policy research. London: Routledge; 1994. p. 173–94. Ritchie J, Spencer L. Analyzing qualitative data. In: Bryman A, Burgess RG, editors. Qualitative data analysis for applied policy research. London: Routledge; 1994. p. 173–94.
Metadata
Title
“It’s Never Just About the HIV:” HIV Primary Care Providers’ Perception of Substance Use in the Era of “Universal” Antiretroviral Medication Treatment
Authors
Aimee N. C. Campbell
Margaret Wolff
Laurel Weaver
Don Des Jarlais
Susan Tross
Publication date
01-03-2018
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-2007-z

Other articles of this Issue 3/2018

AIDS and Behavior 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.